Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...

Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...

Google’s Najeeb Jarrar says that brands that prioritise mindful marketing and champion data privacy will be the ones that ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Vertex Pharma has teamed up with Orum Therapeutics to develop a conditioning regimen, used to prepare patients to receive gene-editing medicines, that it hopes will offer a more tolerable ...

Using the 2 Stage Free Cash Flow to Equity, Emeco Holdings fair value estimate is AU$1.90. Emeco Holdings is estimated to be 49% undervalued based on current share p ...

Helping news, media, brands and institutions leverage our world-class content and cutting-edge services to drive value to their audiences and business. The massive global spectacle that is the Super ...

For the best experience, please enable JavaScript in your browser settings. Former Law Society of Kenya President Nelson Havi. [Screen grab] Former Law Society of ...